Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.78 |
| ▸ | MMP13 | P45452 | 3/20 | 0.78 |
| ▸ | MMP9 | P14780 | 2/20 | 0.78 |
| ▸ | MMP8 | P22894 | 2/20 | 0.78 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15702637 | 1.00 | MMP2 (0.78) | MMP2MMP13MMP9MMP8PKM | |
| SCHEMBL8820296 | 0.90 | MMP2 (0.82) | MMP2MMP13MMP9MMP8HPSE | |
| SCHEMBL8818644 | 0.89 | MMP2 (0.80) | MMP2MMP13MMP9MMP8HPSE | |
| SCHEMBL8820321 | 0.89 | MMP2 (0.80) | MMP2MMP13MMP9MMP8HPSE | |
| SCHEMBL8820325 | 0.89 | MMP2 (0.80) | MMP2MMP13MMP9MMP8HPSE | |
| SCHEMBL8870051 | 0.89 | MMP2 (0.80) | MMP2MMP13MMP9MMP8HPSE | |
| SCHEMBL31032564 | 0.88 | PKM (0.73) | MMP2MMP13MMP9MMP8PKM | |
| SCHEMBL15702613 | 0.88 | PKM (0.73) | MMP2MMP13MMP9MMP8PKM | |
| SCHEMBL15705308 | 0.88 | PKM (0.66) | MMP2MMP13MMP9MMP8PKM | |
| SCHEMBL15702612 | 0.87 | KDM4E (0.87) | MMP2MMP13MMP9MMP8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642749-A1 | CROP NUTRITION AND FORTIFICATION COMPOSITION | Bhukhanwala, Komal (IN) | 2025-11-05 | — | — | EP | disclosed |
| US-20250255936-A1 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE | ENDO OPERATIONS LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| US-20240391989-A1 | METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES | SCHOLAR ROCK, INC. | 2024-11-28 | — | — | US | disclosed |
| US-12072797-B2 | Memory system and non-transitory computer readable recording medium | KIOXIA CORPORATION (JP) | 2024-08-27 | — | — | US | disclosed |
| US-20240261245-A1 | METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY | UNIV NEW YORK (US) | 2024-08-08 | — | — | US | disclosed |
| WO-2024142112-A1 | CROP NUTRITION AND FORTIFICATION COMPOSITION | BHUKHANWALA KOMAL (IN) | 2024-07-04 | — | — | WO | disclosed |
| US-20230281118-A1 | MEMORY SYSTEM AND NON-TRANSITORY COMPUTER READABLE RECORDING MEDIUM | KIOXIA CORPORATION (JP) | 2023-09-07 | — | — | US | disclosed |
| US-11687448-B2 | Memory system and non-transitory computer readable recording medium | KIOXIA CORPORATION (JP) | 2023-06-27 | — | — | US | disclosed |
| US-20230111088-A1 | ANTI-DRUG ANTIBODY ASSAY | HOFFMANN LA ROCHE (US) | 2023-04-13 | — | — | US | disclosed |
| US-20220253381-A1 | MEMORY SYSTEM AND NON-TRANSITORY COMPUTER READABLE RECORDING MEDIUM | KIOXIA CORP (JP) | 2022-08-11 | — | — | US | disclosed |
| US-11347637-B2 | Memory system and non-transitory computer readable recording medium | KIOXIA CORPORATION (JP) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255936-A1 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE | GHSR, VIPR1, VIPR2 | MMP2 4062/4885MMP13 3138/4885MMP9 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.